Compile Data Set for Download or QSAR
Report error Found 5694 Enz. Inhib. hit(s) with Target = 'Heat shock protein HSP 90'
TargetHeat shock protein HSP 90-alpha(Human)
Memorial Sloan-Kettering Cancer Center

US Patent
LigandPNGBDBM313755(US10167285, Example 1)
Affinity DataEC50:  30nMAssay Description:The biochemical assay tests competitive binding of compounds to recombinant Hsp90α protein and also Hsp90 found in cell specific complexes, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
US Patent

TargetHeat shock protein HSP 90-alpha(Human)
Memorial Sloan-Kettering Cancer Center

US Patent
LigandPNGBDBM313756(US10167285, Example (2exp))
Affinity DataEC50:  50.8nMAssay Description:The biochemical assay tests competitive binding of compounds to recombinant Hsp90α protein and also Hsp90 found in cell specific complexes, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
US Patent

TargetHeat shock protein HSP 90-alpha(Human)
Memorial Sloan-Kettering Cancer Center

US Patent
LigandPNGBDBM313757(US10167285, Example 2)
Affinity DataEC50:  8.50E+3nMAssay Description:The biochemical assay tests competitive binding of compounds to recombinant Hsp90α protein and also Hsp90 found in cell specific complexes, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
US Patent

TargetHeat shock protein HSP 90-alpha(Human)
Memorial Sloan-Kettering Cancer Center

US Patent
LigandPNGBDBM313758(US10167285, Example 3)
Affinity DataEC50:  5.00E+3nMAssay Description:The biochemical assay tests competitive binding of compounds to recombinant Hsp90α protein and also Hsp90 found in cell specific complexes, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
US Patent

TargetHeat shock protein HSP 90-alpha(Human)
Memorial Sloan-Kettering Cancer Center

US Patent
LigandPNGBDBM313759(US10167285, Example 4)
Affinity DataEC50:  1.54E+4nMAssay Description:The biochemical assay tests competitive binding of compounds to recombinant Hsp90α protein and also Hsp90 found in cell specific complexes, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
US Patent

TargetHeat shock protein HSP 90-alpha(Human)
Memorial Sloan-Kettering Cancer Center

US Patent
LigandPNGBDBM313760(US10167285, Example 5)
Affinity DataEC50:  38.8nMAssay Description:The biochemical assay tests competitive binding of compounds to recombinant Hsp90α protein and also Hsp90 found in cell specific complexes, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
US Patent

TargetHeat shock protein HSP 90-alpha(Human)
Memorial Sloan-Kettering Cancer Center

US Patent
LigandPNGBDBM313761(US10167285, Example 6)
Affinity DataEC50:  56.5nMAssay Description:The biochemical assay tests competitive binding of compounds to recombinant Hsp90α protein and also Hsp90 found in cell specific complexes, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
US Patent

TargetHeat shock protein HSP 90-alpha(Human)
Memorial Sloan-Kettering Cancer Center

US Patent
LigandPNGBDBM313762(US10167285, Example 7)
Affinity DataEC50:  77.2nMAssay Description:The biochemical assay tests competitive binding of compounds to recombinant Hsp90α protein and also Hsp90 found in cell specific complexes, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
US Patent

TargetHeat shock protein HSP 90-alpha(Human)
Memorial Sloan-Kettering Cancer Center

US Patent
LigandPNGBDBM313763(US10167285, Example 8)
Affinity DataEC50:  50.4nMAssay Description:The biochemical assay tests competitive binding of compounds to recombinant Hsp90α protein and also Hsp90 found in cell specific complexes, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
US Patent

TargetHeat shock protein HSP 90-alpha(Human)
Memorial Sloan-Kettering Cancer Center

US Patent
LigandPNGBDBM313764(US10167285, Example 9)
Affinity DataEC50:  16.1nMAssay Description:The biochemical assay tests competitive binding of compounds to recombinant Hsp90α protein and also Hsp90 found in cell specific complexes, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
US Patent

TargetHeat shock protein HSP 90-alpha(Human)
Memorial Sloan-Kettering Cancer Center

US Patent
LigandPNGBDBM313765(US10167285, Example 10)
Affinity DataEC50:  10nMAssay Description:The biochemical assay tests competitive binding of compounds to recombinant Hsp90α protein and also Hsp90 found in cell specific complexes, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
US Patent

TargetHeat shock protein HSP 90-alpha(Human)
Memorial Sloan-Kettering Cancer Center

US Patent
LigandPNGBDBM313766(US10167285, Example 11)
Affinity DataEC50:  22.3nMAssay Description:The biochemical assay tests competitive binding of compounds to recombinant Hsp90α protein and also Hsp90 found in cell specific complexes, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
US Patent

TargetHeat shock protein HSP 90-alpha(Human)
Memorial Sloan-Kettering Cancer Center

US Patent
LigandPNGBDBM313767(US10167285, Example 12)
Affinity DataEC50: >1.50E+4nMAssay Description:The biochemical assay tests competitive binding of compounds to recombinant Hsp90α protein and also Hsp90 found in cell specific complexes, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
US Patent

TargetHeat shock protein HSP 90-alpha(Human)
Memorial Sloan-Kettering Cancer Center

US Patent
LigandPNGBDBM313768(US10167285, Example 13)
Affinity DataEC50: >1.50E+4nMAssay Description:The biochemical assay tests competitive binding of compounds to recombinant Hsp90α protein and also Hsp90 found in cell specific complexes, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
US Patent

TargetHeat shock protein HSP 90-alpha(Human)
Memorial Sloan-Kettering Cancer Center

US Patent
LigandPNGBDBM313769(US10167285, Example 14)
Affinity DataEC50:  4.60E+3nMAssay Description:The biochemical assay tests competitive binding of compounds to recombinant Hsp90α protein and also Hsp90 found in cell specific complexes, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
US Patent

TargetHeat shock protein HSP 90-alpha(Human)
Memorial Sloan-Kettering Cancer Center

US Patent
LigandPNGBDBM313770(US10167285, Comp 2)
Affinity DataEC50:  120nMAssay Description:The biochemical assay tests competitive binding of compounds to recombinant Hsp90α protein and also Hsp90 found in cell specific complexes, and ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2019
Entry Details
US Patent

TargetHeat shock protein HSP 90-beta(Human)
Conforma Therapeutics

LigandPNGBDBM15374(CHEMBL113690 | 9-butyl-8-(3,4,5-trimethoxybenzyl)-...)
Affinity DataEC50:  4.00E+4nMpH: 7.2 T: 2°CAssay Description:EC50 was defined as the concentration of the compound at which there was 50% degradation of the Her-2/neu protein in MCF7 breast carcinoma cells. Sam...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/16/2008
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetHeat shock protein HSP 90-beta(Human)
Conforma Therapeutics

LigandPNGBDBM15378(PU7 | 9-butyl-8-(2,5-dimethoxybenzyl)-9H-purin-6-a...)
Affinity DataEC50:  1.20E+4nMpH: 7.2 T: 2°CAssay Description:EC50 was defined as the concentration of the compound at which there was 50% degradation of the Her-2/neu protein in MCF7 breast carcinoma cells. Sam...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/16/2008
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetHeat shock protein HSP 90-beta(Human)
Conforma Therapeutics

LigandPNGBDBM20741(9-butyl-8-[(2-chloro-5-methoxyphenyl)methyl]-9H-pu...)
Affinity DataEC50:  2.00E+4nMpH: 7.2 T: 2°CAssay Description:EC50 was defined as the concentration of the compound at which there was 50% degradation of the Her-2/neu protein in MCF7 breast carcinoma cells. Sam...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/16/2008
Entry Details Article
PubMed
TargetHeat shock protein HSP 90-beta(Human)
Conforma Therapeutics

LigandPNGBDBM20742(8-[(2-bromo-5-methoxyphenyl)methyl]-9-butyl-9H-pur...)
Affinity DataEC50:  8.00E+3nMpH: 7.2 T: 2°CAssay Description:EC50 was defined as the concentration of the compound at which there was 50% degradation of the Her-2/neu protein in MCF7 breast carcinoma cells. Sam...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/16/2008
Entry Details Article
PubMed
TargetHeat shock protein HSP 90-beta(Human)
Conforma Therapeutics

LigandPNGBDBM20743(9-butyl-8-[(2-iodo-5-methoxyphenyl)methyl]-9H-puri...)
Affinity DataEC50:  5.00E+3nMpH: 7.2 T: 2°CAssay Description:EC50 was defined as the concentration of the compound at which there was 50% degradation of the Her-2/neu protein in MCF7 breast carcinoma cells. Sam...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/16/2008
Entry Details Article
PubMed
TargetHeat shock protein HSP 90-beta(Human)
Conforma Therapeutics

LigandPNGBDBM20744(9-butyl-8-[(2,5-dimethoxyphenyl)sulfanyl]-9H-purin...)
Affinity DataEC50:  3.50E+3nMpH: 7.2 T: 2°CAssay Description:EC50 was defined as the concentration of the compound at which there was 50% degradation of the Her-2/neu protein in MCF7 breast carcinoma cells. Sam...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/16/2008
Entry Details Article
PubMed
TargetHeat shock protein HSP 90-beta(Human)
Conforma Therapeutics

LigandPNGBDBM20745(8-[(2-iodo-5-methoxyphenyl)sulfanyl]-9-(pent-4-yn-...)
Affinity DataEC50:  280nMpH: 7.2 T: 2°CAssay Description:EC50 was defined as the concentration of the compound at which there was 50% degradation of the Her-2/neu protein in MCF7 breast carcinoma cells. Sam...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/16/2008
Entry Details Article
PubMed
TargetHeat shock protein HSP 90-beta(Human)
Conforma Therapeutics

LigandPNGBDBM20746(8-[(2-iodo-5-methoxyphenyl)sulfanyl]-9-(4-methylpe...)
Affinity DataEC50:  370nMpH: 7.2 T: 2°CAssay Description:EC50 was defined as the concentration of the compound at which there was 50% degradation of the Her-2/neu protein in MCF7 breast carcinoma cells. Sam...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/16/2008
Entry Details Article
PubMed
TargetHeat shock protein HSP 90-beta(Human)
Conforma Therapeutics

LigandPNGBDBM20747(2-fluoro-8-[(2-iodo-5-methoxyphenyl)sulfanyl]-9-(p...)
Affinity DataEC50:  360nMpH: 7.2 T: 2°CAssay Description:EC50 was defined as the concentration of the compound at which there was 50% degradation of the Her-2/neu protein in MCF7 breast carcinoma cells. Sam...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/16/2008
Entry Details Article
PubMed
TargetHeat shock protein HSP 90-beta(Human)
Conforma Therapeutics

LigandPNGBDBM15381(8-[(2-chloro-3,4,5-trimethoxyphenyl)methyl]-2-fluo...)
Affinity DataEC50:  1.70E+3nMpH: 7.2 T: 2°CAssay Description:EC50 was defined as the concentration of the compound at which there was 50% degradation of the Her-2/neu protein in MCF7 breast carcinoma cells. Sam...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/16/2008
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetHeat shock protein HSP 90-beta(Human)
Conforma Therapeutics

LigandPNGBDBM20748(8-[(2-iodo-5-methoxyphenyl)sulfanyl]-9-[3-(pentan-...)
Affinity DataEC50:  210nMpH: 7.2 T: 2°CAssay Description:EC50 was defined as the concentration of the compound at which there was 50% degradation of the Her-2/neu protein in MCF7 breast carcinoma cells. Sam...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/16/2008
Entry Details Article
PubMed
TargetHeat shock protein HSP 90-beta(Human)
Conforma Therapeutics

LigandPNGBDBM20749(9-[3-(butan-2-ylamino)propyl]-8-[(2-iodo-5-methoxy...)
Affinity DataEC50:  210nMpH: 7.2 T: 2°CAssay Description:EC50 was defined as the concentration of the compound at which there was 50% degradation of the Her-2/neu protein in MCF7 breast carcinoma cells. Sam...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/16/2008
Entry Details Article
PubMed
TargetHeat shock protein HSP 90-beta(Human)
Conforma Therapeutics

LigandPNGBDBM20750(8-[(2-iodo-5-methoxyphenyl)sulfanyl]-9-[3-(propan-...)
Affinity DataEC50:  180nMpH: 7.2 T: 2°CAssay Description:EC50 was defined as the concentration of the compound at which there was 50% degradation of the Her-2/neu protein in MCF7 breast carcinoma cells. Sam...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/16/2008
Entry Details Article
PubMed
TargetHeat shock protein HSP 90-beta(Human)
Conforma Therapeutics

LigandPNGBDBM20751(CHEMBL199532 | 9-[3-(tert-butylamino)propyl]-8-[(2...)
Affinity DataEC50:  140nMpH: 7.2 T: 2°CAssay Description:EC50 was defined as the concentration of the compound at which there was 50% degradation of the Her-2/neu protein in MCF7 breast carcinoma cells. Sam...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/16/2008
Entry Details Article
PubMed
TargetHeat shock protein HSP 90-beta(Human)
Conforma Therapeutics

LigandPNGBDBM20752(8-[(2-iodo-5-methoxyphenyl)sulfanyl]-9-{2-[(2-meth...)
Affinity DataEC50:  100nMpH: 7.2 T: 2°CAssay Description:EC50 was defined as the concentration of the compound at which there was 50% degradation of the Her-2/neu protein in MCF7 breast carcinoma cells. Sam...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/16/2008
Entry Details Article
PubMed
TargetHeat shock protein HSP 90-beta(Human)
Conforma Therapeutics

LigandPNGBDBM20753(9-{2-[(2,2-dimethylpropyl)amino]ethyl}-8-[(2-iodo-...)
Affinity DataEC50:  90nMpH: 7.2 T: 2°CAssay Description:EC50 was defined as the concentration of the compound at which there was 50% degradation of the Her-2/neu protein in MCF7 breast carcinoma cells. Sam...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/16/2008
Entry Details Article
PubMed
TargetHeat shock protein HSP 90-beta(Human)
Conforma Therapeutics

LigandPNGBDBM20754(8-(1,3-benzothiazol-2-ylsulfanyl)-9-butyl-9H-purin...)
Affinity DataEC50:  5.00E+3nMpH: 7.2 T: 2°CAssay Description:EC50 was defined as the concentration of the compound at which there was 50% degradation of the Her-2/neu protein in MCF7 breast carcinoma cells. Sam...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2008
Entry Details Article
PubMed
TargetHeat shock protein HSP 90-beta(Human)
Conforma Therapeutics

LigandPNGBDBM20755(9-butyl-8-[(5-chloro-1,3-benzothiazol-2-yl)sulfany...)
Affinity DataEC50:  2.00E+4nMpH: 7.2 T: 2°CAssay Description:EC50 was defined as the concentration of the compound at which there was 50% degradation of the Her-2/neu protein in MCF7 breast carcinoma cells. Sam...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2008
Entry Details Article
PubMed
TargetHeat shock protein HSP 90-beta(Human)
Conforma Therapeutics

LigandPNGBDBM20756(9-butyl-8-[(4-chloro-1,3-benzothiazol-2-yl)sulfany...)
Affinity DataEC50:  1.50E+4nMpH: 7.2 T: 2°CAssay Description:EC50 was defined as the concentration of the compound at which there was 50% degradation of the Her-2/neu protein in MCF7 breast carcinoma cells. Sam...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2008
Entry Details Article
PubMed
TargetHeat shock protein HSP 90-beta(Human)
Conforma Therapeutics

LigandPNGBDBM20757(9-butyl-8-[(6-chloro-1,3-benzothiazol-2-yl)sulfany...)
Affinity DataEC50:  7.00E+3nMpH: 7.2 T: 2°CAssay Description:EC50 was defined as the concentration of the compound at which there was 50% degradation of the Her-2/neu protein in MCF7 breast carcinoma cells. Sam...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2008
Entry Details Article
PubMed
TargetHeat shock protein HSP 90-beta(Human)
Conforma Therapeutics

LigandPNGBDBM20758(CHEMBL213262 | 9-butyl-8-[(7-chloro-1,3-benzothiaz...)
Affinity DataEC50:  180nMpH: 7.2 T: 2°CAssay Description:EC50 was defined as the concentration of the compound at which there was 50% degradation of the Her-2/neu protein in MCF7 breast carcinoma cells. Sam...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2008
Entry Details Article
PubMed
TargetHeat shock protein HSP 90-beta(Human)
Conforma Therapeutics

LigandPNGBDBM20759(8-[(7-bromo-1,3-benzothiazol-2-yl)sulfanyl]-9-buty...)
Affinity DataEC50:  330nMpH: 7.2 T: 2°CAssay Description:EC50 was defined as the concentration of the compound at which there was 50% degradation of the Her-2/neu protein in MCF7 breast carcinoma cells. Sam...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2008
Entry Details Article
PubMed
TargetHeat shock protein HSP 90-beta(Human)
Conforma Therapeutics

LigandPNGBDBM20760(9-butyl-8-[(7-fluoro-1,3-benzothiazol-2-yl)sulfany...)
Affinity DataEC50:  200nMpH: 7.2 T: 2°CAssay Description:EC50 was defined as the concentration of the compound at which there was 50% degradation of the Her-2/neu protein in MCF7 breast carcinoma cells. Sam...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2008
Entry Details Article
PubMed
TargetHeat shock protein HSP 90-beta(Human)
Conforma Therapeutics

LigandPNGBDBM20761(9-butyl-8-[(7-methyl-1,3-benzothiazol-2-yl)sulfany...)
Affinity DataEC50:  300nMpH: 7.2 T: 2°CAssay Description:EC50 was defined as the concentration of the compound at which there was 50% degradation of the Her-2/neu protein in MCF7 breast carcinoma cells. Sam...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2008
Entry Details Article
PubMed
TargetHeat shock protein HSP 90-beta(Human)
Conforma Therapeutics

LigandPNGBDBM20762(9-butyl-8-[(6,7-dichloro-1,3-benzothiazol-2-yl)sul...)
Affinity DataEC50:  2.50E+4nMpH: 7.2 T: 2°CAssay Description:EC50 was defined as the concentration of the compound at which there was 50% degradation of the Her-2/neu protein in MCF7 breast carcinoma cells. Sam...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2008
Entry Details Article
PubMed
TargetHeat shock protein HSP 90-beta(Human)
Conforma Therapeutics

LigandPNGBDBM20763(9-butyl-8-[(7-methoxy-1,3-benzothiazol-2-yl)sulfan...)
Affinity DataEC50:  190nMpH: 7.2 T: 2°CAssay Description:EC50 was defined as the concentration of the compound at which there was 50% degradation of the Her-2/neu protein in MCF7 breast carcinoma cells. Sam...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2008
Entry Details Article
PubMed
TargetHeat shock protein HSP 90-beta(Human)
Conforma Therapeutics

LigandPNGBDBM20764(9-butyl-8-[(7-ethoxy-1,3-benzothiazol-2-yl)sulfany...)
Affinity DataEC50:  1.00E+5nMpH: 7.2 T: 2°CAssay Description:EC50 was defined as the concentration of the compound at which there was 50% degradation of the Her-2/neu protein in MCF7 breast carcinoma cells. Sam...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2008
Entry Details Article
PubMed
TargetHeat shock protein HSP 90-beta(Human)
Conforma Therapeutics

LigandPNGBDBM20765(8-[(7-chloro-1,3-benzothiazol-2-yl)sulfanyl]-9-eth...)
Affinity DataEC50:  200nMpH: 7.2 T: 2°CAssay Description:EC50 was defined as the concentration of the compound at which there was 50% degradation of the Her-2/neu protein in MCF7 breast carcinoma cells. Sam...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2008
Entry Details Article
PubMed
TargetHeat shock protein HSP 90-beta(Human)
Conforma Therapeutics

LigandPNGBDBM20766(8-[(7-chloro-1,3-benzothiazol-2-yl)sulfanyl]-9-pro...)
Affinity DataEC50:  250nMpH: 7.2 T: 2°CAssay Description:EC50 was defined as the concentration of the compound at which there was 50% degradation of the Her-2/neu protein in MCF7 breast carcinoma cells. Sam...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2008
Entry Details Article
PubMed
TargetHeat shock protein HSP 90-beta(Human)
Conforma Therapeutics

LigandPNGBDBM20767(8-[(7-chloro-1,3-benzothiazol-2-yl)sulfanyl]-9-pen...)
Affinity DataEC50:  700nMpH: 7.2 T: 2°CAssay Description:EC50 was defined as the concentration of the compound at which there was 50% degradation of the Her-2/neu protein in MCF7 breast carcinoma cells. Sam...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2008
Entry Details Article
PubMed
TargetHeat shock protein HSP 90-beta(Human)
Conforma Therapeutics

LigandPNGBDBM20768(2-{6-amino-8-[(7-chloro-1,3-benzothiazol-2-yl)sulf...)
Affinity DataEC50:  150nMpH: 7.2 T: 2°CAssay Description:EC50 was defined as the concentration of the compound at which there was 50% degradation of the Her-2/neu protein in MCF7 breast carcinoma cells. Sam...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2008
Entry Details Article
PubMed
TargetHeat shock protein HSP 90-beta(Human)
Conforma Therapeutics

LigandPNGBDBM20769(3-{6-amino-8-[(7-chloro-1,3-benzothiazol-2-yl)sulf...)
Affinity DataEC50:  90nMpH: 7.2 T: 2°CAssay Description:EC50 was defined as the concentration of the compound at which there was 50% degradation of the Her-2/neu protein in MCF7 breast carcinoma cells. Sam...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2008
Entry Details Article
PubMed
TargetHeat shock protein HSP 90-beta(Human)
Conforma Therapeutics

LigandPNGBDBM20770(4-{6-amino-8-[(7-chloro-1,3-benzothiazol-2-yl)sulf...)
Affinity DataEC50:  130nMpH: 7.2 T: 2°CAssay Description:EC50 was defined as the concentration of the compound at which there was 50% degradation of the Her-2/neu protein in MCF7 breast carcinoma cells. Sam...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2008
Entry Details Article
PubMed
TargetHeat shock protein HSP 90-beta(Human)
Conforma Therapeutics

LigandPNGBDBM20771(diethyl (2-{6-amino-8-[(7-chloro-1,3-benzothiazol-...)
Affinity DataEC50:  30nMpH: 7.2 T: 2°CAssay Description:EC50 was defined as the concentration of the compound at which there was 50% degradation of the Her-2/neu protein in MCF7 breast carcinoma cells. Sam...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2008
Entry Details Article
PubMed
Displayed 1 to 50 (of 5694 total ) | Next | Last >>
Jump to: